business
Novo Raises Forecast as Wegovy Pill Fuels Sales
Novo Nordisk A/S said this year’s declines won’t be as bad as initially expected thanks to the new Wegovy pill, which helped fuel sales in the first quarter. For the year, the worst drop for both profit and sales will be 12%, compared with 13% earlier. Bloomberg’s Sanne Wass reports from Copenhagen.
Read full story on Bloomberg Markets → More top storiesAlso covered by
CNBC
Wegovy pill sales smash forecasts after launch as Novo Nordisk hikes guidance
Healthline
Foundayo: FDA Requests More Safety Data for Wegovy Alternative GLP-1 Pill
Yahoo Finance
Eli Lilly’s (LLY) Weight Loss Pill is Better Than Novo’s, Says Jim Cramer
Bloomberg Tech
Infineon Sales Forecast Beats as AI Boosts Power Chip Business
Aggregated and edited by the Scoop newsroom. We surface news from Bloomberg Markets alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop